ADHD Studies

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

We are currently working on one study of ADHD.

Neural Markers of ADHD Across Childhood

Brief Description:

In this study, we are interested in how neuroimaging can improve the diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in young children.  In particular, we aim to investigate (1) how novel methods of EEG analysis might enable more accurate predictions of which children who exhibit ADHD symptoms before age 7 will remain diagnosed with ADHD after age 7; and (2) how the neural correlates of cognitive control, as measured by fMRI, differ between 5-7 year-olds with high and low levels of ADHD symptomatology, and how these neural markers might predict diagnostic status after age 7.

Eligibility for Participation:

We are currently recruiting 3-7 year-olds.

Participation Details:

This study involves one 2-hour visit to our EEG laboratory at Boston Children's Hospital, where we can provide a free parking spot.  Following this visit is a second session where children ages 5-7 can participate in the fMRI component of our study.  Children will be asked to participate in a short session in a few years so that we can look at stability and change in diagnostic status.  Each session is fun and children will receive rewards, snacks, and play time if they need a break.  Compensation up to $100 will also be provided to you for your time.

Full Description:

Currently, 50% of children who are diagnosed with ADHD before the age of 7 will no longer have ADHD by the time they are 8. Most of these diagnoses are made using symptom checklists. Because brain development progresses rapidly between the ages of 3-7, which means behaviors can change dramatically as well, it may be the case that these checklists produce different results across this age range. In other words, they may not be the best tool for making a stable diagnosis in young children. In this study, we hope to use neuroimaging to better identify which children will continue on with a diagnosis of ADHD and which will not. 

Improving the accuracy of ADHD diagnosis in young children would allow doctors to better determine which children need treatment and which do not. A better understanding of what’s happening at the level of the brain may also help to determine which of the many treatment options available would work best for a child with ADHD. Furthermore, for the 50% of children who will not go on to have ADHD, we may be able to identify whether their behaviors are simply developmental or whether they come from other, unidentified issues that can then be treated appropriately.

Research Contact:

If you are interested in participating or would like to learn more, please contact Kelly Kehm at or call 857-218-5228!

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
More optionsSearch
Condition & Treatments
Search for a Condition or Treatment:
View allSearch
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO